New probiotic mix by Biopolis shown to help reduce use of topical steroids by atopic dermatitis patients

New probiotic mix by Biopolis shown to help reduce use of topical steroids by atopic dermatitis patients


VALENCIA, Spain, Dec. 5, 2017— Biopolis, majority owned by Archer Daniels Midland Company (NYSE: ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients.

Atopic Dermatitis (AD) is an inflammatory skin disease that affects 20 percent of children worldwide. It’s the most common form of eczema and typically involves symptoms such as redness, dry skin and an intense itch. AD can significantly reduce the quality of life for patients and their families. Furthermore, children suffering from AD have an increased risk of other atopic disorders, including asthma, allergic rhinitis and chronic sinusitis. Steroids are the most commonly prescribed medication for the treatment of AD and often have undesirable side effects.

Clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patents. JAMA Dermatology has been publishing scientific research since 1883 and is considered to be one of the most relevant and highly reputed journals within the dermatology field.

The research was conducted by Dr. Vicente Navarro-López and co-workers and involved 50 AD patients ages 4 to 17. The study involved a probiotic mixture in the form of a bulk powder that was made from three different Biopolis’ proprietary culture strains. The culture mix was provided to the patients as a supplement, in capsule form, taken orally. It was designed so that the probiotics were administered together with topical corticosteroids, given the supplementary nature of the probiotic treatment.

The study was randomized, double-blinded and placebo-controlled. In summarizing the outcomes of the 12-week study, the researchers stated that: “The mixture of probiotics was effective in reducing SCORAD (Scoring Atopic Dermatitis) index and reducing the use of topical steroids in patients with moderate AD.”

“These results illustrate the tremendous potential of probiotics used in this study to really make a difference to the quality of life for these young AD patients,” said Daniel Ramón Vidal, VP R&D, ADM Bioactives. “This study was directed at children with moderate Atopic dermatitis, and given the success and positive results we’ve seen, we are now planning future studies amongst children with both mild and severe Atopic dermatitis, as well as in adults with similar symptoms to continue to evaluate the potential of this mixture.”

Further information about this probiotic mixture can be requested from

About Biopolis
Biopolis has expertise in the application of biotechnology in the pharmaceutical, food and chemical industry, and specializes mainly in the development and production of functional ingredients such as probiotics and in the design of microorganisms that act as cellular factories for the production of metabolites with added value.
Established in 2003, Biopolis was created in order to pursue excellence as a tool to market with strong science support in the development of high added value products and R&D services. Biopolis acts as a transmission belt within the industry, facilitating the transfer of knowledge to society.
The company is located in the University of Valencia’s Science Park. The building is a 2000m2 infrastructure with 11 laboratories and 2 production plants. These plants have the most demanding industry certifications (ISO, GMP, Halaal). The capabilities of the facility allow it to serve both the food industry and the chemical-pharmaceutical sector.

About ADM
For more than a century, the people of Archer Daniels Midland Company (NYSE: ADM) have transformed crops into products that serve the vital needs of a growing world. Today, we’re one of the world’s largest agricultural processors and food ingredient providers, with approximately 32,000 employees serving customers in more than 160 countries. With a global value chain that includes approximately 500 crop procurement locations, 250 ingredient manufacturing facilities, 38 innovation centers and the world’s premier crop transportation network, we connect the harvest to the home, making products for food, animal feed, industrial and energy uses. Learn more at

Press contact
Aurelie Giles / +41 21 702 84 00

LEWIS Communications
Marta Llibre / +34 93 222 00 25